It is important to point out that BRAF inhibitors are active only in tumors where V600 BRAF mutations result in constitutively active monomers, whereas the same inhibitors give rise to paradoxical tumor promoting effects in RAS mutated melanomas because of their ability to induce allosteric activation through homo- or hetero-dimerization of wild type RAF isoforms [7,8]. This evidence concerns the gene BRAF and melanoma.